Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2025 14:20 ET | Source: BCC Research LLC

Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030

Boston, Oct. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Anti-Parkinson's Drugs: Global Markets to 2030” is projected to grow from $6.1 billion in 2025 to $9.2...
August 18, 2025 04:12 ET | Source: Research and Markets

Dementia and Movement Disorder Treatment Market Outlook Report and Company Analysis 2025-2029

Dublin, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The "Dementia and Movement Disorder Treatment Market 2025-2029" has been added to ResearchAndMarkets.com's offering. The dementia and movement disorder...
January 29, 2024 11:23 ET | Source: Research and Markets

Treatment Syndromes Dementia Movement Disorders Market Global Industry Analysis and Forecast 2031 - Leading Pharmaceutical Companies Aim to Address Rising Incidence of Cognitive Defects

Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Treatment Syndromes Dementia Movement Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product,...
November 09, 2023 08:30 ET | Source: PHARMA TWO B LTD

Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders

Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and dopaminergic side effects...
November 07, 2023 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...
August 28, 2023 07:00 ET | Source: PHARMA TWO B LTD

Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®

Sub-group analyses of patients with early Parkinson's disease (PD) at different age groups or baseline disease severities who were treated with P2B001 showed consistently greater symptomatic control...
April 23, 2023 08:30 ET | Source: PHARMA TWO B LTD

Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting

Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole, with significantly...
December 14, 2022 10:47 ET | Source: Clinical Ink

Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs

Horsham, PA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Horsham, Pa.; December 14, 2022 — Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization...
January 11, 2022 13:10 ET | Source: CenExel Clinical Research

CenExel Clinical Research Acquires Rocky Mountain Movement Disorders Center

Salt Lake City, Utah, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of Rocky Mountain Movement Disorders Center’s clinical research site...
December 10, 2021 11:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Host Movement Disorder Day on December 17, 2021

BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...